Human SDR2 cDNA clone
US6090579A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 16, 1997 |
| Grant date | Jul 18, 2000 |
| Priority date | — |
| Expiry date | Dec 16, 2017 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
SDR2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SDR2 polypeptides and polynucleotides in the design of protocols for the treatment of cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflamation, cerebellar degeneration, Alzheimer's disease, Parkinsons disease, multiple sclerosis, amylotrophic lateral sclerosis, head injury damage, and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan and viral infections, among others, and diagnostic assays for such conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.